Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

KEYNOTE-061 investigators

研究成果: Article同行評審

378 引文 斯高帕斯(Scopus)

指紋 深入研究「Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial」主題。共同形成了獨特的指紋。

Medicine & Life Sciences